Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

10x Genomics (TXG) Acquisitions (2021 - 2022)

10x Genomics' Acquisitions history spans 2 years, with the latest figure at $2.5 million for Q4 2022.

On a quarterly basis, Acquisitions changed N/A to $2.5 million in Q4 2022 year-over-year; TTM through Dec 2023 was $4.0 million, a 0.0% change, with the full-year FY2022 number at $4.0 million, down 26.62% from a year prior.
Acquisitions hit $2.5 million in Q4 2022 for 10x Genomics, up from $1.5 million in the prior quarter.
Over the last five years, Acquisitions for TXG hit a ceiling of $5.5 million in Q1 2021 and a floor of $1.5 million in Q3 2022.